The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

The following is a summary of “Comparative Effectiveness of qSOFA, CURB-65, and PSI in Predicting Pneumonia Hospitalization ...

NEW YORK, May 19 (UPI) --Finding and treating people with undiagnosed asthma or chronic obstructive pulmonary disease improved their health and led ... "This is the world's first study to find people ...

Key Takeaways Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) ...

Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal ...

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...

健康风险增加:COPD合并高血压患者不但会出现高血压疾病、COPD疾病自身引起的健康问题,还会导致中风、心脏病发作等发生率明显升高,甚至会引起较为严重的并发症问题,以上并发症在对患者生活质量产生影响的同时,还会对患者的生命安全产生威胁。

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

While smoking is a key risk factor for chronic obstructive pulmonary disease (COPD), significant prevalence also exists among ...